DexCom(US:DXCM) Globenewswire·2025-12-13 18:26Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [2][5] - A lead plaintiff is a representative party who directs the litigation on behalf of other class members, and a motion must be filed by December 29, 2025, to serve in this role [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [4] - It is claimed that the enhancements to the G7 were overstated, and the true scope of the issues was downplayed, leading to increased regulatory scrutiny and potential legal repercussions for DexCom [4] - The public statements made by DexCom during the Class Period are alleged to have been materially false and misleading, resulting in investor damages when the truth was revealed [4]